INTRODUCING DARESBURY PROTEINS LTD.
Authentic mammalian proteins for high-end applications
Production of biotherapeutics and their reagents using mammalian-based expression systems remains the mainstay of the industry to maintain post-translational modifications required for specific and efficacious drug targets.
Daresbury Proteins Ltd specializes in mammalian recombinant protein production and cell line development which can be transferred into a third party’s cGMP setting.
As an emerging biotech, we developed our proprietary approach while delivering various proteins for cutting-edge research. Our experience and know-how allow us to obtain difficult-to-express proteins in a short period of time with uncompromising quality. We have seen that our stable expression vector system can increase protein expression by up to 50-fold when compared to alternative mammalian expression systems.
To our academic and industrial partners, we bring our extensive knowledge relating to expression of a wide range of product classes including those that are difficult to express, development of research cell lines and production of candidate targets.
WHAT WE DO
Novel Expression Platform For Mammalian Recombinants.
Our novel proprietary expression vectors support stable, high level expression of a broad range of product classes from key, industry focussed mammalian-based production systems.
Focussing on product quality, our proprietary expression technologies support high titre production using a rapid pool approach to deliver our clients targets without the need for additional clonal selection and expansion. Our aim is to support our clients goal of rapidly assessing the functionality of their candidates whilst reducing cost and risk by removing the barriers associated with clonal cell line development.
RECOMBINANT PROTEIN PRODUCTION
Fact. Effective. Challenging Targets.
Daresbury Proteins can generate rapid pools and research cell lines from a range of production backgrounds including CHO-K1 and HEK293 and are happy to discuss each of our clients’ specific needs focussed on the production of high quality targets and reagents.
Our capabilities include:
Sub-cloning of a coding DNA sequence into our proprietary vectors. We strongly recommend host-cell based codon optimisation of the coding DNA insert to increase expression level. This service is provided by our partner, Dapcel Inc, who use their award-winning codon-optimisation algorithm. Alternatively, we can use customer-provided DNA sequence and primers for PCR amplification to introduce into our expression vectors.
Generation of stable rapid pools and cryopreservation of Master Cell Stock. If preferred by our clients, then we are able to support the generation of clonal cell lines for research purposes.
Production of target recombinants and supporting analytical package to confirm suitability of candidate targets.
Please contact us with your specific project.
Active Proteins. Reliable Reagents.
We have produced excellent proteins which have been used in academic research and featured in high impact publications. Almost all of our catalogue proteins were one-of-a-kind when we produced them for university-based scientists, unavailable commercially elsewhere. As a result, our recombinants have been used as rare antigens to generate highly specific antibodies, develop unique assays and produce ground-breaking data.
Our proteins are supplied in a liquid buffered formulation. Secondary structures of our full-length soluble recombinants confer high stability even after days of storage at ambient temperature ensuring their authentic function and activity.
Human recombinant Fibroblast Growth Factor Receptor 1, FGFR1b, (Uniprot P11362-19), aa 22-376, C-term 10xHis
Human recombinant Fibroblast Growth Factor Receptor 1, FGFR1c, (Uniprot P11362-7), aa 22-374, C-term 10xHis
Human recombinant Fibroblast Growth Factor Receptor 2, FGFR2b, (Uniprot P21802-3), aa 22-378, C-term 10xHis
Human recombinant Fibroblast Growth Factor Receptor 2, FGFR2c, (Uniprot P21802-1), aa 22-377, C-term 10xHis
Human recombinant Fibroblast Growth Factor Receptor 3, FGFR3b, (Uniprot P22607-2), aa 23-377, C-term 10xHis
Human recombinant Fibroblast Growth Factor Receptor 3, FGFR3c, (Uniprot P22607-1), aa 23-375, C-term 10xHis
Human recombinant Fibroblast Growth Factor Receptor 4, FGFR4, (Uniprot P22455), aa 22-369, C-term 10xHis
Human recombinant Phospholipase A2 Receptor 1, PLA2R, (Uniprot Q13018), aa 21-1397, C-term 10xHis
Human recombinant Phospholipase A2 Receptor 1, PLA2R, (Uniprot Q13018), aa 21-663, C-term 10xHis
Human recombinant Phospholipase A2 Receptor 1, PLA2R, (Uniprot Q13018), aa 21-515, C-term 10xHis
Human recombinant Phospholipase A2 Receptor 1, PLA2R, (Uniprot Q13018), aa 21-173, C-term 10xHis
Human recombinant Thrombospondin Type-1 Domain-Containing Protein 7A, THSD7A, (Uniprot Q9UPZ6), aa 48-1606, C-term 10xHis
Human recombinant Thrombospondin Type-1 Domain-Containing Protein 7A, THSD7A, (Uniprot Q9UPZ6), aa 48-1171, C-term 10xHis
Human recombinant Vascular Adhesion Protein-1, VAP-1, (Uniprot Q16853), aa 29-763, N-term 10xHis
Human recombinant Ecto-5'-nucleotidase or CD73 (cluster of differentiation 73), CD73, (Uniprot P21589), aa 27-549, C-term 6xHis
Human recombinant Amyloid Precursor Protein, alpha form, APPα, (Isoform APP695 Uniprot P05067-4), aa 18-612, N-term 10xHis
Human recombinant Amyloid Precursor Protein, beta form, APPβ, (Isoform APP695 Uniprot P05067-4), aa 18-596, N-term 10xHis
Human recombinant Autotaxin, Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2, ATX, ENPP2, (Uniprot Q13822), aa 49-863, C-term 10xHis
SARS-CoV-2 trimeric Spike protein, D614G mutant, European variant, S protein, S, (Uniprot P0DTC2), aa 16-1213, C-term 8xHis
Human recombinant Angiotensin-converting Enzyme 2, ACE2 (Uniprot Q9BYF1), aa 19-740, C-term 10xHis
SARS-CoV-2 trimeric Spike protein, UK mutant, B.1.1.7 cluster, Variant of Concern 202012/01, S protein, S, (Uniprot P0DTC2), aa 16-1211, C-term 8xHis.
WHAT PEOPLE SAY
Daniel J. Williamson, PhD
Principal Scientist at Iksuda Therapeutics
Iksuda Therapeutics partnered with Daresbury Proteins to create a stable cell line and generate a recombinant IgG1 human antibody. The expression system delivered substantially more material than was required by the project, which was completed on-time, on-budget and importantly, of an appropriate quality. Communication with Daresbury Proteins was excellent throughout the course of the project with detailed updates being provided on a regular basis whilst the team were able to accommodate changes in the work plan to suit the needs of the project.
Dr Andrea Balogh
Semmelweis University, Budapest
The recombinant human ATX custom designed and manufactured by Daresbury protein in the shortest time possible, is reliable and stable, high quality product providing excellent results in repeated measurements and the best value for money.
GET IN TOUCH
Daresbury Proteins Ltd., Sci-Tech Daresbury, Daresbury Labs, Keckwick Lane, Warrington WA4 4AD, United Kingdom
+44 (0) 7398623734